Company Profile
Adaptive Biotechnologies Stock Price, News & Analysis
- Ticker:
- ADPT
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Adaptive Biotechnologies is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
17.23 USD (-0.81%)
Close
Last updated: June 23, 2026 at 00:00
2.76B USD
Market cap
Why the stock is moving
ADPT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Adaptive Biotechnologies is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Adaptive Biotechnologies follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Adaptive Biotechnologies sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Source: Adaptive Biotechnologies
- 02
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Source: Adaptive Biotechnologies
- 03
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Source: Adaptive Biotechnologies
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies (ADPT) most recently closed at 17.23 USD, a -0.81% move versus the previous session.
What is the market cap of Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies currently has a market capitalization of 2.76B USD on BioPharmSignal.
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ADPT stock listed?
Adaptive Biotechnologies (ADPT) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Adaptive Biotechnologies is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Adaptive?
Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Adaptive Biotechnologies targeting with Adaptive?
Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Biotechnologies?
Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.